TSE:VRX - Valeant Pharmaceuticals International Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$0.00
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Valeant Pharmaceuticals International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
C$0.00
This price target is based on 0 analysts offering 12 month price targets for Valeant Pharmaceuticals International in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a NaN upside from the last price of C$0.00.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Valeant Pharmaceuticals International. This rating has held steady since June 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
6/27/2018Royal Bank of CanadaBoost Price TargetSector PerformC$19.00 ➝ C$25.00
i
11/8/2017Royal Bank of CanadaReiterated RatingSector PerformC$23.00
i
11/8/2017TD SecuritiesUpgradeHold ➝ BuyC$25.50
i
10/20/2017Royal Bank of CanadaLower Price TargetSector PerformC$22.50
i
7/12/2017TD SecuritiesBoost Price TargetHoldC$26.00
i
6/29/2017Cantor FitzgeraldReiterated RatingOverweight
i
Rating by L. Chen at Cantor Fitzgerald
6/19/2017Royal Bank of CanadaReiterated RatingSector PerformC$25.00
i
6/9/2017Royal Bank of CanadaReiterated RatingSector PerformC$26.00
i
5/23/2017Royal Bank of CanadaReiterated RatingSector PerformC$26.00
i
5/10/2017TD SecuritiesLower Price TargetHoldC$20.50
i
5/10/2017ScotiabankBoost Price TargetSector PerformC$19.00
i
5/10/2017Royal Bank of CanadaBoost Price TargetSector PerformC$26.00
i
4/26/2017ScotiabankLower Price TargetSector PerformC$16.00
i
4/18/2017Royal Bank of CanadaReiterated RatingOutperform
i
4/3/2017Royal Bank of CanadaSet Price TargetSector PerformC$24.00
i
3/27/2017Royal Bank of CanadaReiterated RatingSector PerformC$24.00
i
3/20/2017Royal Bank of CanadaReiterated RatingSector PerformC$21.00 ➝ C$18.00
i
3/1/2017TD SecuritiesReiterated RatingHoldC$18.50
i
3/1/2017ScotiabankReiterated RatingSector PerformC$15.00
i
2/28/2017Royal Bank of CanadaReiterated RatingSector PerformC$29.00
i
2/17/2017TD SecuritiesReiterated RatingHoldC$18.50
i
2/17/2017ScotiabankLower Price TargetSector PerformC$17.00 ➝ C$15.00
i
2/6/2017Royal Bank of CanadaReiterated RatingSector PerformC$38.00
i
1/23/2017Royal Bank of CanadaReiterated RatingSector PerformC$38.00
i
1/16/2017Royal Bank of CanadaReiterated RatingSector PerformC$38.00
i
1/11/2017ScotiabankReiterated RatingSector PerformC$17.00
i
12/19/2016Royal Bank of CanadaBoost Price TargetSector PerformC$38.00 ➝ C$38.50
i
12/15/2016Morgan StanleyDowngradeOverweight ➝ Equal Weight
i
12/12/2016Royal Bank of CanadaReiterated RatingSector PerformC$38.00
i
11/28/2016Royal Bank of CanadaReiterated RatingSector PerformC$39.00
i
11/18/2016Royal Bank of CanadaReiterated RatingSector PerformC$39.00
i
11/10/2016TD SecuritiesLower Price TargetHoldC$38.50 ➝ C$18.00
i
11/9/2016ScotiabankLower Price TargetSector PerformC$32.00 ➝ C$17.00
i
11/9/2016Royal Bank of CanadaLower Price TargetSector PerformC$47.00 ➝ C$39.00
i
11/1/2016ScotiabankLower Price TargetSector PerformC$34.00 ➝ C$32.00
i
10/31/2016Royal Bank of CanadaReiterated RatingSector PerformC$47.00
i
10/25/2016Royal Bank of CanadaReiterated RatingSector PerformC$46.50
i
10/11/2016Royal Bank of CanadaReiterated RatingSector PerformC$36.00 ➝ C$35.00
i
10/3/2016Royal Bank of CanadaReiterated RatingOutperformC$46.00
i
9/26/2016Royal Bank of CanadaReiterated RatingSector PerformC$46.00
i
9/20/2016Royal Bank of CanadaReiterated RatingSector Perform
i
9/13/2016Royal Bank of CanadaReiterated RatingSector Perform
i
9/7/2016Royal Bank of CanadaReiterated RatingSector Perform
i
8/23/2016Royal Bank of CanadaReiterated RatingSector PerformC$46.50
i
8/10/2016TD SecuritiesReiterated RatingBuyC$38.00
i
7/25/2016ScotiabankLower Price TargetSector PerformC$35.00 ➝ C$32.00
i
7/20/2016TD SecuritiesReiterated RatingHoldC$38.00
i
7/14/2016TD SecuritiesReiterated RatingHoldC$38.00
i
7/12/2016Royal Bank of CanadaReiterated RatingSector Perform
i
6/27/2016Royal Bank of CanadaReiterated RatingSector Perform
i
6/20/2016TD SecuritiesReiterated RatingHoldC$38.00
i
6/20/2016Royal Bank of CanadaReiterated RatingSector Perform
i
6/14/2016Royal Bank of CanadaReiterated RatingSector Perform
i
6/8/2016TD SecuritiesLower Price TargetC$45.00 ➝ C$38.00
i
6/8/2016Royal Bank of CanadaReiterated RatingSector PerformC$58.00 ➝ C$33.00
i
6/2/2016Royal Bank of CanadaLower Price TargetSector PerformC$74.00 ➝ C$58.00
i
5/24/2016Royal Bank of CanadaReiterated RatingSector Perform
i
4/26/2016Royal Bank of CanadaReiterated RatingSector Perform
i
4/18/2016Royal Bank of CanadaReiterated RatingSector PerformC$83.00
i
3/17/2016TD SecuritiesBoost Price TargetHoldC$45.00 ➝ C$110.00
i
3/16/2016ScotiabankReiterated RatingSector Perform
i
Rating by A. Ridgeway at Scotiabank
(Data available from 3/4/2016 forward)
Valeant Pharmaceuticals International logo
Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

1,232,408 shs

Average Volume

1,382,994 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Valeant Pharmaceuticals International?

The following equities research analysts have issued reports on Valeant Pharmaceuticals International in the last twelve months:
View the latest analyst ratings for VRX.

What is the current price target for Valeant Pharmaceuticals International?

0 Wall Street analysts have set twelve-month price targets for Valeant Pharmaceuticals International in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Valeant Pharmaceuticals International in the next year.
View the latest price targets for VRX.

What is the current consensus analyst rating for Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VRX.

What other companies compete with Valeant Pharmaceuticals International?

How do I contact Valeant Pharmaceuticals International's investor relations team?

Valeant Pharmaceuticals International's physical mailing address is 2150 Saint-Elzear Blvd W, LAVAL, QC H7L 4A8, Canada. The specialty pharmaceutical company's listed phone number is +1-514-7446792. The official website for Valeant Pharmaceuticals International is www.valeant.com.